dantrolene has been researched along with Parkinson Disease in 9 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "After 9 years of treatment for Parkinson's disease, a 68-year-old woman developed the complications of neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) while she was still receiving levodopa, bromocriptine and amantadine hydrochloride." | 8.78 | Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. ( Ogawa, N; Yamawaki, Y, 1992) |
| "Dantrolene was effective on the elevated COK level and FUT-175 was effective on the DIC, and symptoms of NMS and DIC were completely improved after a period of 14 days." | 6.38 | [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease]. ( Ogawa, N; Yamawaki, Y, 1991) |
| "After 9 years of treatment for Parkinson's disease, a 68-year-old woman developed the complications of neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) while she was still receiving levodopa, bromocriptine and amantadine hydrochloride." | 4.78 | Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. ( Ogawa, N; Yamawaki, Y, 1992) |
| "Dantrolene was effective on the elevated COK level and FUT-175 was effective on the DIC, and symptoms of NMS and DIC were completely improved after a period of 14 days." | 2.38 | [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease]. ( Ogawa, N; Yamawaki, Y, 1991) |
| "She was diagnosed with neuroleptic malignant syndrome." | 1.39 | [Case of neuroleptic malignant syndrome following open heart surgery for thoracic aortic aneurysm with parkinson's disease]. ( Ando, Y; Sakamoto, M; Shindo, Y; Shinoda, M; Tateda, T, 2013) |
| "In the patients with Parkinson's disease, it is sometimes provoked by discontinuation of anti-Parkinsonism agents." | 1.32 | A case of malignant syndrome associated with a parkinsonism patient. ( Nomura, S; Sanga, M, 2003) |
| "In 22 patients with idiopathic Parkinson's disease we observed a sudden worsening of motor symptoms and severe akinesia during hospitalization because of infectious diseases, bone fractures, surgery for gastrointestinal tract diseases, and iatrogenic causes." | 1.32 | Acute akinesia or akinetic crisis in Parkinson's disease. ( Armellino, K; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A, 2003) |
| "The status epilepticus was also attenuated by the use of thiamylal sodium." | 1.30 | [A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation]. ( Miyoshi, T; Motomura, S; Osoegawa, M; Tamura, K; Yamanaka, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shinoda, M | 1 |
| Sakamoto, M | 1 |
| Shindo, Y | 1 |
| Ando, Y | 1 |
| Tateda, T | 1 |
| Sanga, M | 1 |
| Nomura, S | 1 |
| Thomas, A | 1 |
| Iacono, D | 1 |
| Luciano, AL | 1 |
| Armellino, K | 1 |
| Onofrj, M | 1 |
| Linazasoro, G | 1 |
| Van Blercom, N | 1 |
| Castro, A | 1 |
| Dapena, MD | 1 |
| Ward, C | 1 |
| Osoegawa, M | 1 |
| Motomura, S | 1 |
| Yamanaka, H | 1 |
| Tamura, K | 1 |
| Miyoshi, T | 1 |
| Yamawaki, Y | 2 |
| Ogawa, N | 2 |
| Imoto, Y | 1 |
| Fukuda, Y | 1 |
| Yokoyama, H | 1 |
| Miyake, T | 1 |
2 reviews available for dantrolene and Parkinson Disease
| Article | Year |
|---|---|
Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.
Topics: Aged; Antithrombins; Benzamidines; Dantrolene; Disseminated Intravascular Coagulation; Female; Guani | 1992 |
[Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease].
Topics: Aged; Benzamidines; Dantrolene; Disseminated Intravascular Coagulation; Female; Guanidines; Humans; | 1991 |
7 other studies available for dantrolene and Parkinson Disease
| Article | Year |
|---|---|
[Case of neuroleptic malignant syndrome following open heart surgery for thoracic aortic aneurysm with parkinson's disease].
Topics: Aged, 80 and over; Anesthesia; Aortic Aneurysm, Thoracic; Cardiac Surgical Procedures; Dantrolene; E | 2013 |
A case of malignant syndrome associated with a parkinsonism patient.
Topics: Antiparkinson Agents; Dantrolene; Fluid Therapy; Humans; Male; Middle Aged; Muscle Relaxants, Centra | 2003 |
Acute akinesia or akinetic crisis in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Cross Infection; Dantrolene; Drug Therapy, Combina | 2003 |
Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.
Topics: Analgesics, Non-Narcotic; Anti-Infective Agents; Antiparkinson Agents; Combined Modality Therapy; Co | 2004 |
Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
Topics: Aged; Antiparkinson Agents; Confusion; Dantrolene; Deep Brain Stimulation; Dehydration; Dopamine Age | 2005 |
[A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation].
Topics: Anticoagulants; Antiparkinson Agents; Bromocriptine; Dantrolene; Disseminated Intravascular Coagulat | 1999 |
[Rigidity abolished by intravenous dantrolene in a patient with Parkinson's disease under spinal anesthesia].
Topics: Aged; Anesthesia, Spinal; Dantrolene; Female; Femoral Fractures; Humans; Muscle Rigidity; Parkinson | 1992 |